NUPLAZID (nda207318)- (EQ 17MG BASE,EQ 10MG BASE)

Generic Name	PIMAVANSERIN TARTRATE	Innovator	ACADIA PHARMS INC
Dosage	EQ 17MG BASE,EQ 10MG BASE
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2030-Apr-29	NCE Excl Expiry	2021-Apr-29
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
1	0	0

Other Developers

Total Other Developers	4

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 17MG BASE	**	**	-	-	-
EQ 10MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of NUPLAZID